Collision of Three Pandemics: The Coexistence of Cervical Cancer, HIV Infection, and Prior Tuberculosis in the Sub-Saharan Country of Botswana

Zetola, Nicola M.; Grover, Surbhi; Modongo, Chawangwa; Chiyapo, Sebathu; Nsingo-Bvochora, Memory; Narasimhamurthy, Mohan; Lin, Lilie L.; Jarvis, Joseph N; Shin, Sanghyuk S.; Robertson, Erle S.

doi:10.1200/jgo.2015.001701

Cited by 12 publications

(17 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the control u3 is at the maximum value of 100% for the first 1.2 years and then steadily declines to zero at time, t=4.5 years. This simulation results conforms with the epidemiological report in the introduction section that gynaecologic TB is a risk factor for oncogenic HPV infection (and subsequent cancer infection) [37]. Hence, if we focus on TB treatment controls, it can significantly reduce the burden of the co-infection of oncogenic HPV and TB in a population.…”

Section: Strategy Bsupporting

confidence: 86%

“…Epidemiological evidences have proven that 80% of global cancer cases are attributed to the oncogenic Human papillomavirus (HPV) [2]. In a study carried out by Zetola et al [37], it was revealed that prior TB infection is mostly common among patients with cases of cervical cancer. Likewise, Zhao et al [39], in another study, showed that TB infection is associated with high vulnerability to oncogenic HPV infection.…”

Section: Introductionmentioning

confidence: 99%

“…Likewise, Zhao et al [39], in another study, showed that TB infection is associated with high vulnerability to oncogenic HPV infection. According to Zetola et al [37], oncogenic HPV and tuberculosis always co-exist, and the immune suppression caused by cancer (which is a consequence of oncogenic HPV) can result in latent TB re-activation, hence, leading to high mortality. In addition, persistent gynecologic TB infection, resulting in chronic inflammation, could be a high risk factor in the progression of oncogenic HPV infection to cervical cancer [37,39].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A co-infection model for Oncogenic HPV and TB with Optimal Control and Cost-Effectiveness Analysis

Omame

Okuonghae

2020

Preprint

View full text Add to dashboard Cite

A co-infection model for oncogenic Human papillomavirus (HPV) and Tuberculosis (TB), with optimal control and cost-effectiveness analysis is studied and analyzed to assess the impact of controls against incident infection and against infection with HPV by TB infected individuals as well as optimal TB treatment in reducing the burden of the co-infection of the two diseases in a population. The co-infection model is shown to exhibit the dynamical property of backward bifurcation when the associated reproduction number is less than unity. Furthermore, it is shown that TB and HPV re-infection parameters (ϕp ≠ 0 and σT ≠ 0) as well as TB exogenous re-infection term (ϵ1 ≠ 0) oncogenic HPV-TB co-infection model. The global asymptotic stability of the disease-free equilibrium of the co-infection model is also proven not to exist, when the associated reproduction number is below unity. The necessary conditions for the existence of optimal control and the optimality system for the co-infection model is established using the Pontryagin's Maximum Principle. Uncertainty and global sensitivity analysis are also carried out to determine the top ranked parameters that drive the dynamics of the co-infection model, when the associated reproduction numbers as well as the infected populations are used as response functions. Numerical simulations of the optimal control model reveal that the intervention strategy which combines and implements control against HPV infection by TB infected individuals as well as TB treatment control for dually infected individuals is the most cost-effective of all the control strategies for the control and management of the burden of oncogenic HPV and TB co-infection.

show abstract

Section: Strategy Bsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A co-infection model for Oncogenic HPV and TB with Optimal Control and Cost-Effectiveness Analysis

Omame

Okuonghae

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…4 Human immunodeficiency virus (HIV) infection has been associated with increasing incidence of HIV-associated cancers in the population, such as cervical cancer, with previous studies reporting up to two thirds (65%) of cervical cancer patients to be HIV positive. 5 Although cervical cancer is a recognized health system challenge, the stage of disease at presentation, associated factors, and clinical outcomes have not been well documented. 6 This study describes the clinical stage at presentation, clinical and sociodemographic factors associated with stage of disease at presentation, and the short-term clinical outcomes among new cervical cancer patients admitted at the Princess Marina Hospital (PMH), a tertiary center in the country's capital.…”

mentioning

confidence: 99%

Predictors of Locally Advanced Disease at Presentation and Clinical Outcomes Among Cervical Cancer Patients Admitted at a Tertiary Hospital in Botswana

Nassali¹,

Melese²,

Nkuba

et al. 2018

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…Current predictions suggest that more than 5700 people will become infected with HIV every day, which corresponds to approximately 240 every hour. Moreover, HIV infection can promote the progression of associated diseases, such as tuberculosis (TB) (Zetola et al ., ). Many resource‐limited regions with a high rate of HIV also have a high TB prevalence rate due to lack of screening tests and efficient treatment (Meintjes et al ., ; Murray et al ., ).…”

Section: Introductionmentioning

confidence: 97%

The potential of plant systems to break the HIV‐TB link

Habibi

Daniell

Soccol

et al. 2019

Plant Biotechnology Journal

View full text Add to dashboard Cite

Summary Tuberculosis (TB) and human immunodeficiency virus (HIV) can place a major burden on healthcare systems and constitute the main challenges of diagnostic and therapeutic programmes. Infection with HIV is the most common cause of Mycobacterium tuberculosis (Mtb), which can accelerate the risk of latent TB reactivation by 20‐fold. Similarly, TB is considered the most relevant factor predisposing individuals to HIV infection. Thus, both pathogens can augment one another in a synergetic manner, accelerating the failure of immunological functions and resulting in subsequent death in the absence of treatment. Synergistic approaches involving the treatment of HIV as a tool to combat TB and vice versa are thus required in regions with a high burden of HIV and TB infection. In this context, plant systems are considered a promising approach for combatting HIV and TB in a resource‐limited setting because plant‐made drugs can be produced efficiently and inexpensively in developing countries and could be shared by the available agricultural infrastructure without the expensive requirement needed for cold chain storage and transportation. Moreover, the use of natural products from medicinal plants can eliminate the concerns associated with antiretroviral therapy (ART) and anti‐TB therapy (ATT), including drug interactions, drug‐related toxicity and multidrug resistance. In this review, we highlight the potential of plant system as a promising approach for the production of relevant pharmaceuticals for HIV and TB treatment. However, in the cases of HIV and TB, none of the plant‐made pharmaceuticals have been approved for clinical use. Limitations in reaching these goals are discussed.

show abstract

Collision of Three Pandemics: The Coexistence of Cervical Cancer, HIV Infection, and Prior Tuberculosis in the Sub-Saharan Country of Botswana

Cited by 12 publications

References 9 publications

A co-infection model for Oncogenic HPV and TB with Optimal Control and Cost-Effectiveness Analysis

A co-infection model for Oncogenic HPV and TB with Optimal Control and Cost-Effectiveness Analysis

Predictors of Locally Advanced Disease at Presentation and Clinical Outcomes Among Cervical Cancer Patients Admitted at a Tertiary Hospital in Botswana

The potential of plant systems to break the HIV‐TB link

Contact Info

Product

Resources

About